ArticleFrontiers in pharmacology2023

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.

Yan Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.